-
公开(公告)号：US20180221500A1
公开(公告)日：2018-08-09
申请号：US15810830
申请日：2017-11-13
IPC分类号： A61K47/64 , G01N33/574 , A61K47/54 , C07K14/00 , C07K7/06 , A61K51/08 , A61K49/14 , A61K49/08 , A61K49/00 , A61K48/00 , A61K41/00 , A61K38/12 , A61K38/04 , A61K33/24 , A61K9/127 , C07K14/705
CPC分类号： A61K47/64 , A61K9/127 , A61K33/24 , A61K38/04 , A61K38/12 , A61K41/0095 , A61K47/54 , A61K47/6415 , A61K47/6425 , A61K48/0033 , A61K49/0056 , A61K49/085 , A61K49/14 , A61K51/08 , A61K51/088 , C07K7/06 , C07K14/001 , C07K14/705 , G01N33/574
摘要： An environmentally sensitive membrane binding polypeptide, pH (low)-sensitive membrane peptide (pHLIP) has improved insertion kinetics balanced with solubility to selectively target acidic tissues.
-
72.发明申请公开(公告)号：US20180207253A1
公开(公告)日：2018-07-26
申请号：US15918788
申请日：2018-03-12
发明人： Toni WEINSCHENK , Andrea MAHR , Jens FRITSCHE , Phillip MUELLER , Anita WIEBE , Sara KUTSCHER
IPC分类号： A61K39/00 , G01N33/68 , C07K14/725 , A61K38/04 , C07K7/00 , C07K7/06 , C07K7/08 , C07K14/435 , A61K35/17 , C12N15/115 , C12N5/0783 , C07K16/18 , C07K14/74 , A61K35/12
CPC分类号： A61K39/0011 , A61K35/17 , A61K38/04 , A61K2035/124 , A61K2039/5154 , A61K2039/5158 , C07K7/00 , C07K7/06 , C07K7/08 , C07K14/435 , C07K14/7051 , C07K14/70539 , C07K16/18 , C07K2317/70 , C07K2319/40 , C12N5/0636 , C12N15/115 , C12N2310/16 , C12N2501/998 , G01N33/6803
摘要： A method of eliciting an immune response in a patient who has a cancer includes administering to said patient a composition containing a population of activated T cells that selectively recognize the cancer cells in the patient that aberrantly express a peptide consisting of the amino acid sequence of GVYDGEEHSV (SEQ ID NO: 303), in which the peptide is in a complex with an MHC molecule.
-
公开(公告)号：US10030050B2
公开(公告)日：2018-07-24
申请号：US15500178
申请日：2014-08-05
申请人： CAREGEN CO., LTD.
发明人： Yong Ji Chung , Eun Mi Kim , Eung Ji Lee , A Reum Han , Hyun Jung Kwon
摘要： A peptide which is formed from an amino acid sequence selected from the group comprising amino acid sequences of SEQ ID NO: 1 to SEQ ID NO: 3, according to the present invention, has osteoclast differentiation and activation inhibition and is highly effective for preventing or treating bone diseases related to the destruction of the bone. A peptide, according to the present invention, reduces expression of cathepsin K and TRAP related to osteoclast differentiation, inhibits nuclear translocation of NF-kB, and ultimately inhibits osteoclast differentiation. Provided is a composition, for preventing or treating bone diseases, comprising the peptide.
-
公开(公告)号：US10005821B2
公开(公告)日：2018-06-26
申请号：US11853497
申请日：2007-09-11
CPC分类号： C07K14/21 , A61K38/00 , A61K38/04 , A61K38/08 , A61K38/10 , A61K38/164 , C07K7/00 , Y02A50/395 , Y02A50/411
摘要： The present invention provides modified cupredoxin derived peptides with pharmacologic activity that have improved pharmacokinetic properties, and methods to use them to treat mammals suffering from various conditions related to the pharmacologic activities. Modifications of the cupredoxin derived peptides include amino acid sequence variants and structural derivations that increase the plasma half-life of the peptide, increase the specific activity of the pharmacologic activity, decrease immunogenicity, and decrease the biotransformation of the peptides. The modified cupredoxin derived peptides can be used in methods to treat mammals for cancer, conditions related to inappropriate angiogenesis, viral and bacterial infections, and specifically HIV and malaria, conditions related to ephrin signaling, and to deliver cargo compounds, including diagnostic compounds, to cancer cells.
-
公开(公告)号：US09999659B2
公开(公告)日：2018-06-19
申请号：US15367711
申请日：2016-12-02
申请人： AFFIRIS AG
发明人： Sylvia Brunner , Gergana Galabova , Gabriele Winsauer , Erika Bilcikova , Claudia Juno , Pola Linzmayer-Hirt , Birgit Schuh , Guenther Staffler
CPC分类号： A61K39/0005 , A61K39/385 , A61K39/39 , A61K47/6415 , A61K47/643 , A61K47/646 , A61K2039/55505 , A61K2039/6081 , C12N9/6424 , C12N9/6454 , C12Y304/21061
摘要： The present invention relates to a vaccine capable to induce the formation of antibodies directed to PCSK9 in vivo.
-
公开(公告)号：US09981005B2
公开(公告)日：2018-05-29
申请号：US15025273
申请日：2014-09-29
发明人： George Baillie
CPC分类号： A61K38/08 , G01N33/566 , G01N33/6896 , G01N2333/47 , G01N2500/02 , G01N2800/28 , G01N2800/2814 , G01N2800/30 , G01N2800/52
摘要： The invention relates to the finding that turnover of DISC1 (Disrupted in schizophrenia 1) is mediated by the F-box-containing protein FBXW7 (F-box/WD repeat-containing protein 7). The sequence within DISC1 that binds to FBXW7 and targets DISC1 for turnover by the ubiquitin-proteasome system is identified. The invention provides antagonists that inhibit this interaction and methods of using these antagonists to decrease DISC1 turnover, for example in treatment of neuropsychiatric disorders, as well as methods of identifying new antagonists.
-
77.发明授权公开(公告)号：US09963497B2
公开(公告)日：2018-05-08
申请号：US15035571
申请日：2014-12-07
发明人： Raymond Kaempfer , Anat Shirvan , Gila Arad
IPC分类号： C07K14/705 , A61K38/04 , A61K38/17 , A61K45/06 , A61K38/00
CPC分类号： C07K14/70521 , A61K38/00 , A61K38/1774 , A61K45/06
摘要： The present disclosure relates to a method for the treatment of a non-pathogen associated inflammatory disorders in a subject in need thereof, comprising administering to said subject an isolated peptide which specifically binds to an amino acid sequence within the dimer interface of a T cell costimulatory pathway member, particularly the T cell costimulatory pathway members CD28 and CTLA4. The present disclosure also relates to pharmaceutical compositions comprising the isolated peptide and to use of the peptide in treating of a non-pathogen associated inflammatory disorders.
-
78.发明申请公开(公告)号：US20170368133A1
公开(公告)日：2017-12-28
申请号：US15127022
申请日：2015-03-18
摘要： Disclosed are methods for treating, preventing and alleviating obesity, fatty liver syndrome, diabetes, one or more metabolic syndrome conditions or complications and/or cancer comprising administering an effective amount of ostreolysin, its functionally related variant, or an extract or mushroom extract comprising the same to subjects in need thereof.
-
79.发明申请公开(公告)号：US20170362296A1
公开(公告)日：2017-12-21
申请号：US15696206
申请日：2017-09-06
发明人： Yechiel SHAI , Avner FINK , Eliran-Moshe REUVEN , Liraz GALIA
IPC分类号： C07K14/705 , C07K7/08 , C07K4/00 , A61K38/10 , A61K38/04 , A61K38/03 , C07K14/00 , A61K38/16 , A61K38/00
CPC分类号： C07K14/705 , A61K38/00 , A61K38/03 , A61K38/04 , A61K38/10 , A61K38/16 , C07K4/00 , C07K7/08 , C07K14/00 , Y02A50/411
摘要： Peptides are provided that are capable of inhibiting cell activation mediated by a Toll-like receptor (TLR) selected from TLR 1, 2, 4 or 6, said peptide comprising a sequence consisting of, or found within, the sequence of the transmembrane domain of a TLR selected from TLR 1, 2, 4 or 6 and optionally cytoplasmic and extracellular regions flanking the transmembrane domain. These peptides as well as pharmaceutical composition comprising them are useful for the treatment of TLR-mediated disease.
-
公开(公告)号：US09701716B2
公开(公告)日：2017-07-11
申请号：US14750709
申请日：2015-06-25
申请人： Centaur, Inc.
IPC分类号： A01N37/18 , A61K38/04 , C07K7/08 , A01N47/44 , C07K14/47 , A01N37/46 , A01N63/02 , A61K38/00
摘要： The present disclosure relates to antimicrobial agents and methods of using such agents. The disclosure includes antimicrobial agents having broad spectrum antimicrobial activity, nucleic acids and amino acid sequences encoding such antimicrobial agents, as well as methods of using the antimicrobial agents. The antimicrobial agents of the disclosure may be used to reduce survival of a microbe, as an antimicrobial therapeutic, in microbial treatment protocols, and in research, as well as other uses related to reducing microbe survival. In addition, the disclosure also includes compositions, as well as articles of manufacture, that comprise a broad spectrum antimicrobial agent.
-
-
-
-
-
-
-
-
-
搜索结果
2916 条记录 (耗时 0.053 秒)
